• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Drug ‐Drug Interaction of Letermovir and Atorvastatin in Healthy Participants
AbstractLetermovir (MK-8228/AIC246) is a cytomegalovirus (CMV) DNA terminase complex inhibitor for CMV prophylaxis in adult patients undergoing hematopoietic stem cell transplant. It is cytochrome P450 (CYP) 3A inhibitor and inhibits organic anion transporting polypeptide 1B1/3 and breast cancer resistance protein transporters. Atorvastatin (ATV), a commonly used treatment for hypercholesterolemia, is a substrate of organic anion transporting polypeptide 1B1, potentially breast cancer resistance protein, and CYP3A. As letermovir may be coadministered with ATV, the effect of multiple-dose letermovir 480  mg once daily on t...
Source: Clinical Pharmacology in Drug Development - February 14, 2022 Category: Drugs & Pharmacology Authors: Jacqueline B. McCrea, Karsten Menzel, Adedayo Adedoyin, Carolyn R. Cho, Sabrina Fox ‐Bosetti, Sreeraj Macha, Tian Zhao, Fang Liu, Deborah Panebianco, S. Aubrey Stoch, Marian Iwamoto Tags: Original Article Source Type: research

Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants
Clin Pharmacol Drug Dev. 2022 Feb 14. doi: 10.1002/cpdd.1071. Online ahead of print.ABSTRACTLetermovir (MK-8228/AIC246) is a cytomegalovirus (CMV) DNA terminase complex inhibitor for CMV prophylaxis in adult patients undergoing hematopoietic stem cell transplant. It is cytochrome P450 (CYP) 3A inhibitor and inhibits organic anion transporting polypeptide 1B1/3 and breast cancer resistance protein transporters. Atorvastatin (ATV), a commonly used treatment for hypercholesterolemia, is a substrate of organic anion transporting polypeptide 1B1, potentially breast cancer resistance protein, and CYP3A. As letermovir may be coad...
Source: Clinical Genitourinary Cancer - February 14, 2022 Category: Cancer & Oncology Authors: Jacqueline B McCrea Karsten Menzel Adedayo Adedoyin Carolyn R Cho Sabrina Fox-Bosetti Sreeraj Macha Tian Zhao Fang Liu Deborah Panebianco S Aubrey Stoch Marian Iwamoto Source Type: research

Cancers, Vol. 11, Pages 1300: Assessing Cachexia Acutely after Autologous Stem Cell Transplant
ncey Jose M. Garcia Autologous hematopoietic stem cell transplantation (AHCT) is an accepted strategy for various hematologic malignancies that can lead to functional impairment, fatigue, muscle wasting, and reduced quality of life (QOL). In cancer cachexia, these symptoms are associated with inflammation, hypermetabolism, and decreased anabolic hormones. The relative significance of these factors soon after AHCT setting is unclear. The purpose of this study was to characterize the acute effects of AHCT on physical function, body composition, QOL, energy expenditure, cytokines, and testosterone. Outcomes were assesse...
Source: Cancers - September 3, 2019 Category: Cancer & Oncology Authors: Lindsey J. Anderson Chelsea Yin Raul Burciaga Jonathan Lee Stephanie Crabtree Dorota Migula Kelsey Geiss-Wessel Haiming M. Liu Solomon A. Graf Thomas R. Chauncey Jose M. Garcia Tags: Article Source Type: research

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Model Provides Stratification of Patients According to Probability of SIS Discontinuation
CONCLUSIONS:Older age, bone marrow as a source of stem cells, T-cell depletion, matched related donor and a full matched donor increase the likelihood of discontinuation of SIS after allogeneic HCT. In addition, the severity of aGVHD and cGVHD significantly affects the chance of SIS discontinuation. The proposed risk score stratifies patients into well-defined groups according to the chance of SIS discontinuation. Further studies in a larger number of patients are strongly recommended to validate this finding. Prospective validation is also warranted to confirm the utility of the risk score as a clinical tool for estimatio...
Source: Blood - November 21, 2018 Category: Hematology Authors: Bautista, M. R., Law, A., Lam, W., Michelis, F. V., Thyagu, S., Viswabandya, A., Kumar, R., Lipton, J. H., Messner, H. A., Kim, D. D. H. Tags: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II Source Type: research

Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms
Abstract Juvenile inflammatory myopathies represent a heterogeneous group of rare and potentially fatal disorders of unknown aetiology, characterised by inflammation and proximal and symmetric muscle weakness. Beyond many similarities, specific clinical, laboratoristic and histopathologic features underlie different subsets with distinguishing demographic, prognostic and therapeutic peculiarities. Over time, several forms of inflammatory idiopathic myopathies have been described, including macrophagic myofascitis, immune-mediated necrozing myopathy and the spectrum of amyopathic dermatomyositis that include hypomy...
Source: Clinical Reviews in Allergy and Immunology - October 1, 2015 Category: Allergy & Immunology Source Type: research

Statins side effects are minimal, study argues
ConclusionThis meta-analysis pooled results from 29 studies and has shown a very small increased risk of newly diagnosed diabetes mellitus. This is the same as the decreased risk of any cause of death in people taking statins, compared to placebo, to prevent a heart attack or stroke.The researchers point out some limitations to the meta-analysis: Each study did not report on all of the side effects, meaning that for each category of side effect, the number of participants differed. The side effect categories were only included if at least 500 people had reported suffering from it. This means there may be numerous other si...
Source: NHS News Feed - March 13, 2014 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news